Clinical trials: Metastatic Breast Carcinoma
Solid Tumor, Triple Negative Breast Cancer
RX-5902 Treatment of Subjects With Triple Negative Breast Cancer
The purpose of this Phase 2 portion of the study is to use the dose and schedule of RX-5902 identified in the phase 1 to treat subjects with triple negative breast cancer.
- Trial name
- NCT02003092
- Testing
- RX-5902
- Where
- 8 sites in United States
- Volunteers
- 18 people
- Sponsor
- Rexahn Pharmaceuticals, Inc.
Metastatic Breast Cancer, Locally Advanced Breast Cancer
Study of Artesunate in Metastatic Breast Cancer
The purpose of this study is to evaluation the tolerability of an add-on therapy with artesunate with a duration of 4 weeks in patients with advanced breast cancer.
- Trial name
- ARTIC-M33/2 (NCT00764036)
- Testing
- artesunate
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- Heidelberg University
Metastatic Breast Cancer
Characterization & Comparison of Drugable Mutations in Primary and Metastatic Tumors, CTCs and cfDNA in MBCpatients
Characterization of the driver mutations in an individual metastatic breast cancer patient is critical for many reasons. Effective targeted therapies require identifying genomic alterations in the tumoral tissue.
- Trial name
- MIRROR (NCT02626039)
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Neoplasm Metastasis, Lung Neoplasms
Characterization of Brain Metastases
The purpose is to characterize tumour biological markers in brain metastases tissue from patients with different primary tumour by using ex vivo techniques as high-resolution magic angle spinning MR spectroscopy and micro array.
- Conditions
- Neoplasm Metastasis, Lung Neoplasms, Breast Neoplasms, Melanoma
- Trial name
- NCT00184275
- Where
- Norway
- Volunteers
- 26 people
- Sponsor
- Norwegian University of Science and Technology
Prostate Cancer, Breast Cancer
An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...
Objectives: To find out the maximum tolerated dose of the GI-6207 vaccine (the highest dose that does not cause unacceptable side effects), and to evaluate any side effects. To see if GI-6207 has any effect on patients tumors.
- Conditions
- Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer
- Trial name
- NCT00924092
- Testing
- GI-6207 [Recombinant Saccharomyces Cerevisia, (Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)])
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Urothelial Carcinoma, Breast Cancer
Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.
- Conditions
- Metastatic Urothelial Carcinoma, Breast Cancer, TNBC - Triple-Negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
- Trial name
- NCT07671092
- Testing
- RYZ211/212
- Where
- 6 sites in Australia, New Zealand and 1 more
- Volunteers
- 40 people
- Sponsor
- RayzeBio, Inc.
Triple Negative Breast Cancer
Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)
Previous studies in Western country show that triple-negative breast cancer has aggressive clinical and pathological features compared with non-triple negative breast cancer, including onset at a young age, advanced clinical…
- Trial name
- NCT01216111
- Testing
- Paclitaxel Cisplatin, fluorouracil epirubicin cyclophosphamide and docetaxel (FEC-T)
- Volunteers
- 647 people
- Sponsor
- Fudan University
Metastatic Breast Cancer
An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine
The overall purpose of this study is to compare the efficacy, safety and tolerability of indisulam in combination with capecitabine (IC) versus capecitabine (C) monotherapy in patients with metastatic breast cancer who have…
- Trial name
- NCT00165880
- Testing
- E7070
- Where
- 33 sites in Germany, Italy and 3 more
- Volunteers
- 62 people
- Sponsor
- Eisai Limited
Metastatic Breast Cancer
Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study
Women with recurrent or metastatic breast cancer who are hormone receptor positive are candidates for first line hormonal therapy including aromatase inhibitors.
- Trial name
- CONCEPT (NCT04012918)
- Testing
- Capecitabine plus aromatase inhibitor, A.I.
- Where
- Egypt
- Volunteers
- 124 people
- Sponsor
- Ain Shams University
Breast Cancer
Survey Among Healthcare Professionals Treating Patients With Metastatic Breast Cancer in Selected European Countries to Evaluate Their Knowledge on Management of Hyperglycemia When Using Alpelisib
This was a multinational, non-interventional, cross-sectional survey conducted among HCPs based in the EU/EEA who prescribe Piqray.
- Trial name
- NCT05073120
- Testing
- Piqray Prescriber's/HCP guide for hyperglycemia
- Where
- Switzerland
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of combining liposomal doxorubicin with gemcitabine in…
- Trial name
- NCT00027989
- Testing
- gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride
- Where
- 6 sites in United States
- Sponsor
- Pharmatech Oncology
Metastatic Breast Cancer
ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer
The purpose of this study is to evaluate the safety and tolerability of weekly ABI-007 in combination with bevacizumab. The evaluation of progression-free survival of weekly ABI-007 in combination with bevacizumab for patients…
- Trial name
- NCT00394082
- Testing
- ABI-007, Bevacizumab
- Where
- 20 sites in United States
- Volunteers
- 50 people
- Sponsor
- Celgene
Metastatic Breast Cancer, Advanced Breast Cancer
Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment
The purpose of the study is to demonstrate clinical efficacy of the investigational trifunctional bispecific antibody ertumaxomab for treatment of patients with HER-2/neu 1+ or 2+ (FISH-) expressing advanced or metastatic breast…
- Trial name
- NCT00452140
- Testing
- ertumaxomab
- Where
- 5 sites in Austria, France and 3 more
- Volunteers
- 40 people
- Sponsor
- Neovii Biotech
TNBC - Triple-Negative Breast Cancer
The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study
This is a multicenter, open-label, single-arm clinical study designed to evaluate the safety and efficacy of Utidelone plus Tirelizumab and Bevacizumab for advanced or metastatic triple-negative breast cancer (TNBC).
- Trial name
- UTILIZABLE (NCT06125080)
- Testing
- Utidelone, Tirelizumab, Bevacizumab
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Huihua Xiong
Breast Cancer
A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.
This single arm. open-label study will assess the efficacy and safety of Herceptin (trastuzumab) in combination with Xeloda (capecitabine) in patients with metastatic or recurrent HER2-positive breast cancer, refractory to or…
- Trial name
- NCT01290718
- Testing
- capecitabine [Xeloda], trastuzumab [Herceptin]
- Where
- 6 sites in Taiwan
- Volunteers
- 4 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer
This study determines the proportion of metastatic breast cancer patients progression free after 6 months when treated with gemcitabine/ cisplatin/ trastuzumab or gemcitabine/ trastuzumab.
- Trial name
- NCT00201760
- Testing
- Gemcitabine, Trastuzumab, Cisplatin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Kari Kendra
HER2-negative
NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients
This noninterventional, multicenter,retrospective study has been proposed to estimate the prevalence, clinicopathological characteristics,treatment patterns and clinical outcomes of human epidermal growth factor receptor 2…
- Trial name
- iRetroBC (NCT06131424)
- Where
- 31 sites in Argentina, Brazil and 11 more
- Volunteers
- 1,151 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer
Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer
To study the pharmacokinetic profile of the therapeutic schedule in order to demonstrate absence of negative interactions among the 3 drugs administered
- Trial name
- NCT00250874
- Testing
- Liposomal Doxorubicin (Myocet), Docetaxel and Trastuzumab
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- Zeneus Pharma
Metastatic Progressive Castration-resistant Prostate Cancer, Metastatic Progressive Breast Cancer
Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method
The primary objective of the preliminary lead-in study is to determine whether circulating tumor cells in patients with metastatic progressive castration-resistant prostate cancer or metastatic progressive breast cancer can be…
- Trial name
- CTC-EMT (NCT02025413)
- Testing
- Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Duke University
Breast Cancer
Efficacy and Safety Study of LEP-ETU to Treat Metastatic Breast Cancer
LEP-ETU is a novel, proprietary delivery system of paclitaxel developed by NeoPharm, Inc. Paclitaxel (currently marketed as Taxol) is an anti-microtubular network agent and is active in a broad spectrum of malignancies.
- Trial name
- NCT01190982
- Testing
- LEP-ETU
- Where
- 3 sites in India
- Volunteers
- 70 people
- Sponsor
- INSYS Therapeutics Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.